Arranon

Arranon is a brand name of nelarabine, approved by the FDA in the following formulation(s):

ARRANON (nelarabine - injectable; iv (infusion))

• 
  Manufacturer: SMITHKLINE BEECHAM
  
  Approval date: October 28, 2005
  
  Strength(s): 250MG/50ML (5MG/ML) ^[RLD]

Has a generic version of Arranon been approved?

No. There is currently no therapeutically equivalent version of Arranon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arranon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  9-.beta.-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
  Patent 5,424,295
  Issued: June 13, 1995
  Inventor(s): Krenitsky; Thomas A. & Porter; David J. T.
  Assignee(s): Burroughs Wellcome Co.
  The compound 9-B-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine along with its 5'-acetyl and 5'-(4-methoxy-4-oxobutyryl derivatives are disclosed as inhibitors of Varicella Zoster virus (VZV).
  
  Patent expiration dates:
  
  
  • June 13, 2017
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives
  Patent 5,492,897
  Issued: February 20, 1996
  Inventor(s): Krenitsky; Thomas A. & Averett; Devron R. & Koszalka; George W. & Wolberg; Gerald
  Assignee(s): Burroughs Wellcome Co. (141)
  6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.
  
  Patent expiration dates:
  
  
  • February 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
  
  



• 
  Therapeutic methods for using ARA-G derivatives
  Patent 5,747,472
  Issued: May 5, 1998
  Inventor(s): Krenitsky; Thomas Anthony & Averett; Devron Randolph & Koszalka; George Walter & Wolberg; Gerald
  Assignee(s): Glaxo Wellcome Inc.
  6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.
  
  Patent expiration dates:
  
  
  • February 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
  
  
  
  • February 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
  
  
  
  • February 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
  
  



• 
  Tumor treatment with arabinofuranosyl purine derivatives
  Patent 5,821,236
  Issued: October 13, 1998
  Inventor(s): Krenitsky; Thomas Anthony & Averett; Devron Randolph & Koszalka; George Walter
  Assignee(s): Glaxo Wellcome Inc.
  6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.
  
  Patent expiration dates:
  
  
  • February 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 28, 2010 - NEW CHEMICAL ENTITY
  
  
  • October 28, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Arranon Consumer Information (Drugs.com)
• Arranon Consumer Information (Wolters Kluwer)
• Arranon Consumer Information (Cerner Multum)
• Arranon Advanced Consumer Information (Micromedex)
• Arranon AHFS DI Monographs (ASHP)
• Nelarabine Consumer Information (Wolters Kluwer)
• Nelarabine Consumer Information (Cerner Multum)
• Nelarabine Intravenous Advanced Consumer Information (Micromedex)
• Nelarabine AHFS DI Monographs (ASHP)